Nektar Therapeutics 8-K Filing
Ticker: NKTR · Form: 8-K · Filed: Sep 18, 2025 · CIK: 906709
Sentiment: neutral
Filing Stats: 656 words · 3 min read · ~2 pages · Grade level 11.4 · Accepted 2025-09-18 08:56:13
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value NKTR Nasdaq Capital Marke
Filing Documents
- ea0257842-8k_nektar.htm (8-K) — 26KB
- ea025784201ex99-1_nektar.htm (EX-99.1) — 36KB
- ea025784201ex99-2_nektar.htm (EX-99.2) — 59KB
- ex99-1_001.jpg (GRAPHIC) — 1377KB
- ex99-1_002.jpg (GRAPHIC) — 582KB
- ex99-1_003.jpg (GRAPHIC) — 470KB
- ex99-1_004.jpg (GRAPHIC) — 537KB
- ex99-1_005.jpg (GRAPHIC) — 781KB
- ex99-1_006.jpg (GRAPHIC) — 583KB
- ex99-1_007.jpg (GRAPHIC) — 985KB
- ex99-1_008.jpg (GRAPHIC) — 509KB
- ex99-1_009.jpg (GRAPHIC) — 524KB
- ex99-1_010.jpg (GRAPHIC) — 382KB
- ex99-1_011.jpg (GRAPHIC) — 411KB
- ex99-1_012.jpg (GRAPHIC) — 423KB
- ex99-1_013.jpg (GRAPHIC) — 501KB
- ex99-1_014.jpg (GRAPHIC) — 544KB
- ex99-1_015.jpg (GRAPHIC) — 427KB
- ex99-1_016.jpg (GRAPHIC) — 485KB
- ex99-1_017.jpg (GRAPHIC) — 517KB
- ex99-1_018.jpg (GRAPHIC) — 598KB
- ex99-1_019.jpg (GRAPHIC) — 730KB
- ex99-1_020.jpg (GRAPHIC) — 315KB
- ex99-1_021.jpg (GRAPHIC) — 502KB
- ex99-1_022.jpg (GRAPHIC) — 465KB
- ex99-1_023.jpg (GRAPHIC) — 313KB
- ex99-2_001.jpg (GRAPHIC) — 13KB
- 0001213900-25-088792.txt ( ) — 18173KB
- nktr-20250918.xsd (EX-101.SCH) — 3KB
- nktr-20250918_lab.xml (EX-101.LAB) — 33KB
- nktr-20250918_pre.xml (EX-101.PRE) — 22KB
- ea0257842-8k_nektar_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. On September 18, 2025, Nektar Therapeutics ("Nektar") posted slides on its website (www.nektar.com) containing additional information related to certain new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin, as discussed in Item 8.01 below. A copy of the slides is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Information contained on Nektar's website is not incorporated by reference into this Current Report on Form 8-K, and you should not consider any information on, or that can be accessed from, Nektar's website as part of this Current Report on Form 8-K. The information under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing . Nektar undertakes no obligation to update, supplement or amend the material attached hereto as Exhibit 99.1.
01
Item 8.01 Other Events. On September 18, 2025, Nektar announced certain new data from the ongoing REZOLVE-AD Phase 2b study of rezpegaldesleukin. A copy of the press release issued in connection with the announcement is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Slides Titled "Efficacy and Safety of Rezpegaldesleukin, A Selective Regulatory T-Cell-Inducing Interleukin-2 Conjugate, in the Treatment of Atopic Dermatitis: Final Results from the 16-Week Induction of a Randomized Phase 2b Study (REZOLVE AD)". 99.2 Press Release Titled "Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025". 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEKTAR THERAPEUTICS Date: September 18, 2025 By: /s/ Mark A. Wilson Mark A. Wilson Chief Legal Officer and Secretary 2